Core Viewpoint - Allergy Therapeutics is evaluating the possibility of a dual listing on the Hong Kong Stock Exchange while retaining its position on the AIM market, aiming to expand its business in Asia and become a leader in the global allergy treatment sector [1] Company Overview - Allergy Therapeutics is a UK-based biotechnology company focused on allergy immunotherapy [1] Strategic Intent - The company plans to complete the Hong Kong listing by the first half of 2026, subject to approval from the Hong Kong Stock Exchange and the Hong Kong Securities and Futures Commission [1] - The dual listing is intended to broaden the company's investor base by including investors from Hong Kong and mainland China, aligning with its growth objectives in the region [1] - The move is expected to enhance the liquidity of its ordinary shares [1]
新股消息 | 英国生物医药公司Allergy Therapeutics考虑赴港上市
Zhi Tong Cai Jing·2025-11-07 07:32